Cirrhotic Patients Who Have Already Received A Hbv Vaccination With A Conventional Regimen And Who Have Not Responded Characterized By A Level Of Antibody Hbs 10ui Ml At The End Of The Vaccine Regimen clinical trials

Explore recruiting cirrhotic patients who have already received a hbv vaccination with a conventional regimen and who have not responded characterized by a level of antibody hbs 10ui ml at the end of the vaccine regimen clinical trials.

Also recruiting in Europe

Cirrhotic Patients Who Have Already Received A Hbv Vaccination With A Conventional Regimen And Who Have Not Responded Characterized By A Level Of Antibody Hbs 10ui Ml At The End Of The Vaccine Regimen trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Effectiveness and Safety of Intra-Dermal Hepatitis B Vaccination after topical application of IMIQUIMOD, in cirrhotic patients, who did not respond to the conventional vaccine regimen: a pilot study

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Cirrhotic Patients Who Have Already Received A Hbv Vaccination With A Conventional Regimen And Who Have Not Responded Characterized By A Level Of Antibody Hbs 10ui Ml At The End Of The Vaccine Regimen trials by city

Cirrhotic Patients Who Have Already Received A Hbv Vaccination With A Conventional Regimen And Who Have Not Responded Characterized By A Level Of Antibody Hbs 10ui Ml At The End Of The Vaccine Regimen in Toronto Cirrhotic Patients Who Have Already Received A Hbv Vaccination With A Conventional Regimen And Who Have Not Responded Characterized By A Level Of Antibody Hbs 10ui Ml At The End Of The Vaccine Regimen in Vancouver Cirrhotic Patients Who Have Already Received A Hbv Vaccination With A Conventional Regimen And Who Have Not Responded Characterized By A Level Of Antibody Hbs 10ui Ml At The End Of The Vaccine Regimen in Montreal Cirrhotic Patients Who Have Already Received A Hbv Vaccination With A Conventional Regimen And Who Have Not Responded Characterized By A Level Of Antibody Hbs 10ui Ml At The End Of The Vaccine Regimen in Calgary Cirrhotic Patients Who Have Already Received A Hbv Vaccination With A Conventional Regimen And Who Have Not Responded Characterized By A Level Of Antibody Hbs 10ui Ml At The End Of The Vaccine Regimen in Edmonton Cirrhotic Patients Who Have Already Received A Hbv Vaccination With A Conventional Regimen And Who Have Not Responded Characterized By A Level Of Antibody Hbs 10ui Ml At The End Of The Vaccine Regimen in Ottawa Cirrhotic Patients Who Have Already Received A Hbv Vaccination With A Conventional Regimen And Who Have Not Responded Characterized By A Level Of Antibody Hbs 10ui Ml At The End Of The Vaccine Regimen in Winnipeg Cirrhotic Patients Who Have Already Received A Hbv Vaccination With A Conventional Regimen And Who Have Not Responded Characterized By A Level Of Antibody Hbs 10ui Ml At The End Of The Vaccine Regimen in Quebec City Cirrhotic Patients Who Have Already Received A Hbv Vaccination With A Conventional Regimen And Who Have Not Responded Characterized By A Level Of Antibody Hbs 10ui Ml At The End Of The Vaccine Regimen in Hamilton Cirrhotic Patients Who Have Already Received A Hbv Vaccination With A Conventional Regimen And Who Have Not Responded Characterized By A Level Of Antibody Hbs 10ui Ml At The End Of The Vaccine Regimen in Kitchener Cirrhotic Patients Who Have Already Received A Hbv Vaccination With A Conventional Regimen And Who Have Not Responded Characterized By A Level Of Antibody Hbs 10ui Ml At The End Of The Vaccine Regimen in London Cirrhotic Patients Who Have Already Received A Hbv Vaccination With A Conventional Regimen And Who Have Not Responded Characterized By A Level Of Antibody Hbs 10ui Ml At The End Of The Vaccine Regimen in Halifax Cirrhotic Patients Who Have Already Received A Hbv Vaccination With A Conventional Regimen And Who Have Not Responded Characterized By A Level Of Antibody Hbs 10ui Ml At The End Of The Vaccine Regimen in New York Cirrhotic Patients Who Have Already Received A Hbv Vaccination With A Conventional Regimen And Who Have Not Responded Characterized By A Level Of Antibody Hbs 10ui Ml At The End Of The Vaccine Regimen in Los Angeles Cirrhotic Patients Who Have Already Received A Hbv Vaccination With A Conventional Regimen And Who Have Not Responded Characterized By A Level Of Antibody Hbs 10ui Ml At The End Of The Vaccine Regimen in Chicago Cirrhotic Patients Who Have Already Received A Hbv Vaccination With A Conventional Regimen And Who Have Not Responded Characterized By A Level Of Antibody Hbs 10ui Ml At The End Of The Vaccine Regimen in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease